Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 4/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | DDO | Q99489 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30548030 | 0.79 | DAO (0.58) | DAOFLT3KDM4EALDH1A1HPGD | |
| SCHEMBL11386139 | 0.79 | DAO (0.68) | DAOFLT3KDM4EALDH1A1HPGD | |
| SCHEMBL19708446 | 0.77 | DAO (0.55) | DAOFLT3KDM4EALDH1A1HPGD | |
| SCHEMBL30712834 | 0.75 | DAO (0.56) | DAOKDM4EGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL1093711 | 0.75 | DAO (0.56) | DAOKDM4EGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL11658287 | 0.75 | DHODH (0.55) | DAOFLT3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL16767845 | 0.75 | DAO (1.00) | DAOFLT3KDM4EALDH1A1HPGD | |
| SCHEMBL4048274 | 0.75 | FLT3 (0.60) | DAOFLT3KDM4EALDH1A1HPGD | |
| SCHEMBL6135945 | 0.75 | DAO (0.37) | DAOFLT3KDM4EGAAALDH1A1 | |
| SCHEMBL4045458 | 0.74 | RAB9A (0.59) | DAOFLT3KDM4EGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023078398-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2023-05-11 | — | — | WO | disclosed |
| EP-1718608-B1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2013-07-17 | — | — | EP | disclosed |
| US-6995184-B2 | Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors | SANOFI-AVENTIS (FR) | 2006-02-07 | — | — | US | disclosed |
| CN-1234688-C | 3-aroyl indoles and their use as CB2Use of receptor agonists | SANOFI ANVANT (FR) | 2006-01-04 | — | — | CN | disclosed |
| EP-1339679-B1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | SANOFI AVENTIS (FR) | 2005-08-10 | — | — | EP | disclosed |
| CN-1483023-A | 3-arylindole derivatives and their use as cb2 receptor agonists | ʥŵ��-�ϳ�ʵ���ҹ�˾ | 2004-03-17 | — | — | CN | disclosed |
| US-20040034090-A1 | 3-Arylindole derivatives and their use as cb2 receptor agonists | SANOFI-AVENTIS (FR) | 2004-02-19 | — | — | US | disclosed |
| EP-1339679-A1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | Sanofi-Aventis (FR) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042269-A1 | 3-ARYLINDOLE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | SANOFI-SYNTHELABO (FR) | 2002-05-30 | — | — | WO | disclosed |
| US-RE29834-E | PREPARED FROM 4-SULFONYL-1,8-NAPHTHOLACTAMS | BAYER AKTIENGESELLSCHAFT (DE) | 1978-11-14 | — | — | US | disclosed |
| US-3959310-A | BENZINDOLE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034090-A1 | 3-Arylindole derivatives and their use as cb2 receptor agonists | CNR2, CNR1, GPR52 | DAO 2722/4885FLT3 1282/4885KDM4E 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.